GET THE APP

Treatment of HIV by Antiretroviral Therapy
..

Journal of Infectious Diseases and Medicine

ISSN: 2576-1420

Open Access

Editorial - (2022) Volume 7, Issue 5

Treatment of HIV by Antiretroviral Therapy

Ryan Singh*
*Correspondence: Ryan Singh, Department of Medicine, Dalhousie University, Canada, Email:
Department of Medicine, Dalhousie University, Canada

Received: 02-May-2022, Manuscript No. jidm-22-67935; Editor assigned: 09-May-2022, Pre QC No. P-67935; Reviewed: 16-May-2022, QC No. Q-67935; Revised: 23-May-2022, Manuscript No. R-67935; Published: 30-May-2022 , DOI: 10.37421/2576-1420.2022.7.236
Citation: Singh, Ryan. “Treatment of HIV by Antiretroviral Therapy.” J Infect Dis Med 7 (2022): 236.
Copyright: © 2022 Singh R. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Editorial

Antiretroviral therapy refers to any HIV treatment that uses a combination of two or more drugs. A healthcare provider may choose to prescribe a combination of three or more drugs to improve the treatment’s chance of success.

Specialists introduced antiretroviral therapy in 1996 in response to the poor success rate among those taking only one HIV medication at a time. The beginnings of three-drug antiretroviral treatment marked a turning point in the history of HIV treatment. The new treatment design transformed what used to be a diagnosis with a very poor outlook into a manageable condition. Antiretroviral therapy has a twofold effect on the body. It increases the number of immune cells while also decreasing the number of virus cells present in the body.

HIV treatment involves taking medicine that reduces the amount of HIV in your body.

• HIV medicine is called antiretroviral therapy (ART).

• There is no effective cure for HIV. But with proper medical care, you can control HIV.

• Most people can get the virus under control within six months.

• Taking HIV medicine does not prevent transmission of other sexually transmitted diseases.

Treatment reduces the amount of HIV in the blood:

• The amount of HIV in the blood is called viral load.

• Taking your HIV medicine as prescribed will help keep your viral load low and your CD4 cell count high.

• HIV medicine can make the viral load very low (called viral suppression). Viral suppression is defined as having less than 200 copies of HIV per milliliter of blood.

• HIV medicine can make the viral load so low that a test can’t detect it (called an undetectable viral load).

• If your viral load goes down after starting HIV treatment, that means treatment is working. Continue to take your medicine as prescribed.

• If you skip your medications, even now and then, you are giving HIV the chance to multiply rapidly. This could weaken your immune system, and you could become sick.

• Getting and keeping an undetectable viral load (or staying virally suppressed) is the best way to stay healthy and protect others.

Antiretroviral therapy has the following positive effects on HIV:

• Stops it from multiplying in the blood

• Reduces viral load, which is the number of HIV copies in the blood

• Increases the number of CD4 cells, which are immune cells that HIV

targets, to improve immune system function

• Slows down and prevents the development of stage 3 HIV, or AIDS

• Prevents transmission

• Reduces the severity of complications and increases survival rates

• Keeps virus counts low in the blood [1-5]

Acknowledgement

None.

Conflict of Interests

None.

References

  1. Allie, Nasiema, Sergei I. Grivennikov, Roanne Keeton and Nai-Jen Hsu, et al. "Prominent role for T cell-derived tumour necrosis factor for sustained control of Mycobacterium tuberculosis infection." Sci Rep 3 (2013): 1-14.
  2. Indexed at, Crossref, Google Scholar

  3. Amiri-Kordestani, Laleh, Gideon M. Blumenthal, Qiang Casey Xu and Lijun Zhang, et al. "FDA approval: Ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer." Clin Cancer Res 20 (2014): 4436-4441.
  4. Indexed at, Crossref, Google Scholar

  5. Amoury, Manal, Katharina Kolberg, Anh-Tuan Pham, Dmitrij Hristodorov and  Radoslav Mladenov, et al. "Granzyme B-based cytolytic fusion protein targeting EpCAM specifically kills triple negative breast cancer cells in vitro and inhibits tumor growth in a subcutaneous mouse tumor model." Cancer Lett 372 (2016): 201-209.
  6. Indexed at, Crossref, Google Scholar

  7. Anderson, Ana C., Nicole Joller and Vijay K. Kuchroo. "Lag-3, Tim-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation." Immun 44 (2016): 989-1004.
  8. Indexed at, Crossref, Google Scholar

  9. Araki, Koichi, Ben Youngblood and Rafi Ahmed. "Programmed cell death 1-directed immunotherapy for enhancing T-cell function." Cold Spring Harb Symp Quant Biol 78 (2013): 239-247.
  10. Indexed at, Crossref, Google Scholar

arrow_upward arrow_upward